title: The Challenge of Primary Central Nervous System Lymphoma.
abstract: Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor.
authors.affiliation: Division of Hematology/Oncology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.
authors.forename: Julia
authors.initials: J
authors.lastname: Carnevale
authors.affiliation: Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, M1282 Box 1270, San Francisco, CA 94143, USA. Electronic address: jamesr@medicine.ucsf.edu.
authors.forename: James L
authors.initials: JL
authors.lastname: Rubenstein
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000628:therapy; D059248:Chemoradiotherapy / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D000069283:Rituximab; D008727:Methotrexate
keywords: Aggressive lymphoma; Brain tumor; High-dose chemotherapy; NF-κB; Primary CNS lymphoma